Clinical Trials Browser

Phase 1/2 × INDUSTRY × Blood Specimen Collection × Clear all

NCT03860207 2023-09-13

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Phase 1/2 Terminated

12 enrolled 15 charts

Neuroblastoma, Osteosarcoma